Eurofins BioPharma Product Testing Biologics, a biopharmaceutical product bioanalysis company, sets up operations in Lentilly in western Greater Lyon
Eurofins is a global leader in analytical services in the pharmaceutical sector, including vaccines, as well as in the food and environmental fields. It has established its new quality control laboratory for biological medicines in Lentilly, with the support of ONLYLYON Invest.
Founded in Nantes in 1987, Eurofins is a leading company in pharmaceutical, food, and environmental analysis. It employs 62,000 people working across 900 laboratories in 62 countries. The group reported €6.5 billion in revenue for 2023. Its subsidiary, Eurofins BioPharma Product Testing, is dedicated specifically to the analysis of biopharmaceutical products. Now present in more than 22 countries, it operates over 40 laboratories worldwide, including seven in France.
Eurofins has consolidated its Lyon-area activities at a new, modern, and larger site in Lentilly, within the territory of the Communauté de Communes du Pays de l’Arbresle (CCPA), with the opening of its quality control laboratory for biopharmaceutical products—particularly those containing messenger RNA, for which new analytical methods had to be developed. Eurofins BioPharma Product Testing was supported in this project by ONLYLYON Invest, the economic attractiveness program of ONLYLYON & CO—formerly Aderly (Agency for the Economic Development of the Lyon Region).
This site is also designated as a center of excellence for the detection, identification, and typing of microorganisms.
Eurofins, an innovative CRO in the biopharmaceutical field
Eurofins has built unique expertise worldwide. From safety and composition assessments to verification of origin authenticity and purity, the company offers its clients a portfolio of 200,000 analytical methods.
The pharmaceutical product testing company is committed to delivering the most appropriate services by providing accurate results along with expert guidance. In doing so, it contributes to bringing new therapies to market in a secure environment for patients and end users.
Eurofins continually strives for excellence to deliver relevant results as quickly as possible, along with high-standard consulting and expert services. The reliability and precision of the analytical data it produces are at the core of its approach.
The challenge is to rigorously meet international quality and safety standards.
Additionally, its distinctive approach combines expertise, high-quality services, and a strong commitment to innovation and energy performance. Eurofins has invested in technology, information systems, and logistics through research and development programs. In this way, it integrates cutting-edge biotechnology and analytical service tools into its professional practices, offering solutions that are unique on the market and available at accessible prices.
ONLYLYON Invest supports the establishment of healthcare industry companies like Eurofins
A cradle of biotechnological innovation and bio-industries, the Lyon metropolitan area brings together key players in the sector, including companies, laboratories, and institutions. To support public health, the Lyon Metropolitan Authority implements policies favorable to the healthcare sector and facilitates the establishment of companies that strengthen the region’s capabilities in this field.
In this context, ONLYLYON Invest, supported by the Lyon Metropolitan Authority and working in partnership with the Communauté de Communes du Pays de l’Arbresle (CCPA), assisted Eurofins with its establishment. The program coordinated with local stakeholders (the Auvergne-Rhône-Alpes Region, the regional directorate for the economy, employment, labor, and social affairs, ADEME, and Banque des Territoires) to identify financing solutions. It also connected the company with the regional ecosystem focused on building energy performance and supported its recruitment of new talent.
The Lyon region, an ideal location for establishing a healthcare laboratory
Eurofins chose to locate in the Lyon region, drawn by the dynamism of its healthcare sector. After obtaining the necessary authorizations to open a pharmaceutical facility in February 2024, it established its new laboratory in the Charpenay industrial zone, at 12 rue du Parc d’Activités in Lentilly. The site benefits from proximity to rail infrastructure, making it an ideal geographic location.
The 2,000 m² multidisciplinary platform has been operational since March 1, 2024. It houses all the equipment required for quality control analyses of biotherapeutic products. Its key advantage is its “one-stop shop” model, bringing together all activities—biobanking, non-sterile microbiology, sterile microbiology, chemistry, biochemistry, molecular biology, virology, and more—within a single location. The building was also designed with energy efficiency and environmental considerations in mind. It is expected to accommodate up to 120 employees over the next four years.
Eurofins’ arrival represents a unique opportunity at the regional, national, and even European level, as no other laboratory of this kind exists elsewhere. It brings new pharmaceutical production capabilities to the region.